



## **Sentien Biotechnologies Names Richard Ganz as Executive Chairman**

*Appointment Coincides with Company Pursuing COVID-19 Opportunity*

**LEXINGTON, MA, May 15, 2020** – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the appointment of Richard Ganz as Executive Chairman. Mr. Ganz will continue to lead Sentien’s Board of Directors, a role he has filled for the past nine years, as well as work closely with CEO Brian Miller and Sentien’s management team.

Mr. Ganz has more than 30 years of experience in the healthcare industry. His previous roles include Executive-in-Residence for Kairos Venture Investments, Principal of RGA Life Sciences, Chief Operating Officer of Piramal Critical Care, a global pharmaceutical company; President and Chief Executive Officer at Omnisonics Medical Technologies; President of the North American Renal Division for Baxter International, Inc; and Divisional Vice President and General Manager of Vascular Products at Abbott Laboratories.

“We are very pleased that Mr. Ganz has expanded his leadership role with Sentien,” said Sentien CEO, Brian Miller. “His breadth of experience across several areas of the healthcare industry as well as his depth of knowledge in the critical care disease space has made him an invaluable member of our board. Through this new expanded capacity, Mr. Ganz will provide further strategic leadership as we fundraise for clinical expansion for COVID-19.”

“I am very excited to be expanding my role with Sentien’s leadership team as Executive Chairman,” said Mr. Ganz. “While serving as chairman of the board, I have witnessed Sentien’s rapid growth into a clinical-stage company and I continue to believe strongly in the potential of Sentien’s technology to treat systemic inflammatory diseases. I look forward to contributing to the company’s continued growth in this expanded capacity.”

### **About Sentien Biotechnologies**

Sentien Biotechnologies, Inc. is a privately-held, clinical-stage company developing novel ex-vivo cell therapy applications to treat conditions caused by systemic, immune-mediated inflammation. Sentien’s lead product, SBI-101, integrates allogeneic mesenchymal stromal cells (MSCs) within an extracorporeal, hollow-fiber device. By immobilizing MSCs within a blood-filtration device, SBI-101 allows for prolonged exposure of patient blood to the MSCs,

resulting in the dynamic delivery of MSC-secreted factors at doses that are unattainable by direct injection.

SBI-101 is being evaluated in Phase 1b/2a study in subjects with dialysis-requiring acute kidney injury (AKI-D). An interim readout from the clinical study provides evidence of anti-inflammatory and wound healing effects consistent with the SBI-101 therapeutic hypothesis. Building on this therapeutic hypothesis, SBI-101 is being pursued in COVID-19 patients suffering from severe systemic inflammation.

Sentien's technology can be applied to additional systemic inflammatory indications in both acute and chronic diseases, focusing on complex diseases where single-factor agents have not been effective.

For more information, please visit [www.sentienbiotech.com](http://www.sentienbiotech.com).

###

**Media Contact:**

Brian Miller, CEO  
Sentien Biotechnologies, Inc.  
(781) 361-9031  
[info@sentienbiotech.com](mailto:info@sentienbiotech.com)